GESTIÓN EN SALUD PÚBLICA: FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma | FDA

lunes, 4 de abril de 2022

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma | FDA

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)